Cycloalkane amine compound as M2 inhibitor and application thereof

Abstract

The invention discloses a cycloalkane amine compound of a general formula I or II, or pharmaceutically acceptable salt thereof, or substituted group defined in the description; the cycloalkane amine compound of the general formula I or II, or pharmaceutically acceptable salt can be used for preparing medicine for preventing and treating flue; as the M2 ion channel protein inhibitor, the compound can stop copy of the flue virus, and treat influenza, specifically the influenza A.

Description

technical field The patent of the present invention belongs to the field of medicinal chemistry, and relates to cycloalkylamine compounds as M2 inhibitors and their application. technical background Influenza (hereinafter referred to as influenza) is an acute respiratory infectious disease that seriously endangers human health. It is caused by influenza virus and has the characteristics of high prevalence, widespread prevalence and rapid transmission. There have been many worldwide influenza pandemics in history, among which the Spanish flu epidemic in 1918 was the most serious, and more than 20 million people were killed by influenza. In 2009, the "swine flu" that broke out in Mexico is now seriously threatening the lives of human beings all over the world, causing great losses to human life and social economy. At present, the main means of preventing and treating influenza are M2 ion channel protein inhibitors, neuraminidase inhibitors and influenza vaccines (John Beigel...

AI Technical Summary

Problems solved by technology

However, this class of drugs has the following obvious disadvantages (Schnell JR, Chou JJ.Nature.2008, 451(7178): 591-5): (1) it is ineffective against influenza B virus; (2) there are obvious side effects, causing obvious Gastrointestinal adverse reactions; central nervous system side effects, mainly manifested as insomnia, distraction and nervousness; (3) drug-resistant strains are prone to occur during treatment

Although decades have passed since the two single-skeleton drugs were launched, no drugs with new structures have emerged. Most of the inhibitors in research drugs still use adamantane as the backbone, so it is urgent to find drugs with new structures. Inhibitor

Images